Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential

Share:
Related ALNY
Benzinga's Top Upgrades, Downgrades For April 17, 2017
25 Stocks Moving In Friday's Pre-Market Session

In a report published Friday, Deutsche Bank analyst Alethia Young initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and $40.00 price target.

In the report, Young noted, “Alnylam is an early stage company that uses a technology called RNA interference that occurs naturally in the body to silence problematic genes in diseases that were previously deemed un-druggable. We believe Alnylam has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales. We initiate with a Buy rating and a $40 target price.”

Alnylam Pharmaceuticals closed on Thursday at $28.06.

Latest Ratings for ALNY

DateFirmActionFromTo
Apr 2017BMO CapitalInitiates Coverage OnOutperform
Mar 2017UBSInitiates Coverage OnNeutral
Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!